- Stocks
- Pharma & Healthcare
- Nephrocare Health Services
Nephrocare Health Services share price
NSE: NEPHROPLUSPharma & HealthcareMedical Care Facilities
Nephrocare Health Services at a glance
Nephrocare Health Services (NSE: NEPHROPLUS) closed at ₹599.90 on 22 Oct 2026, down 0.84% on the day. With a market capitalisation of ₹6,019 Cr, it ranks 728th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 74.1× trailing earnings, against a return on equity of 6.9% in FY26. Its 52-week range is ₹446.00 (19 Dec 2025) to ₹781.50 (11 Sep 2026); the last close is 23.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹266 Cr (+21.2% year on year) and net profit ₹33 Cr (+34.5%), on a consolidated basis. Promoters held 63.85% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹6,019 CrRank 728 on NSE
- P/E (trailing)
- 74.1×
- Price to book
- 4.54×FY26
- ROE
- 6.9%FY26
- ROCE
- 13.7%FY26
- Debt to equity
- 0.07FY26
- Net profit margin
- 8.0%FY26
- Book value / share
- ₹111.27FY26
- 52-week high
- ₹781.5011 Sep 2026
- 52-week low
- ₹446.0019 Dec 2025
- RSI (14-day)
- 27.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.84% | −2.7% | −20.1% | −11.7% | — |
Nephrocare Health Services quarterly results
| Quarter | Q4 FY25 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | ₹219 Cr | ₹260 Cr | ₹266 Cr |
| Revenue YoY | — | — | +21.2% |
| Net profit | ₹25 Cr | ₹32 Cr | ₹33 Cr |
| Net profit YoY | — | — | +34.5% |
| Net margin | 11.3% | 12.4% | 12.6% |
| EPS | ₹3.05 | ₹3.43 | ₹3.03 |
Nephrocare Health Services financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹286 Cr | ₹318 Cr | ₹437 Cr | ₹566 Cr | ₹756 Cr | — |
| Operating profit | ₹1 Cr | −₹27 Cr | −₹9 Cr | ₹33 Cr | ₹87 Cr | — |
| Net profit | ₹1 Cr | −₹21 Cr | −₹12 Cr | ₹35 Cr | ₹67 Cr | — |
| EPS (₹) | ₹5.00 | −₹131.00 | −₹68.00 | ₹5.00 | ₹8.00 | — |
| Cash from operations | ₹32 Cr | ₹14 Cr | ₹11 Cr | ₹72 Cr | ₹135 Cr | — |
| Total debt | ₹68 Cr | ₹65 Cr | ₹81 Cr | ₹123 Cr | ₹96 Cr | ₹45 Cr |
| Shareholders' equity | ₹249 Cr | ₹392 Cr | ₹389 Cr | ₹410 Cr | ₹580 Cr | ₹1,116 Cr |
Nephrocare Health Services shareholding pattern
| Holder | 16 Dec 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 63.85% | 63.85% | 63.85% | 63.85% |
| Foreign institutions | 3.59% | 9.30% | 9.94% | 8.78% |
| Domestic institutions | 8.68% | 8.10% | 8.65% | 9.05% |
| Non-institutions | 23.88% | 18.74% | 17.56% | 18.32% |
Nephrocare Health Services vs peers
The listed Pharma & Healthcare companies nearest to Nephrocare Health Services by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ENTEROEntero Healthcare Solutions | ₹1,504.20 | −0.19% | +36.0% | ₹6,547 Cr | 57.1 | — |
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
| SPARCSun Pharma Advanced Research Company | ₹176.82 | −1.22% | +35.4% | ₹5,738 Cr | 3.7 | — |
| SENORESSenores Pharmaceuticals | ₹1,233.30 | +0.35% | +71.0% | ₹5,680 Cr | 46.7 | — |
| INNOVACAPInnova Captab | ₹983.60 | +0.57% | +17.9% | ₹5,629 Cr | 40 | — |
| FDCFDC | ₹339.20 | −0.24% | −22.1% | ₹5,523 Cr | — | — |
Ask anything about Nephrocare Health Services
Pivot answers on the live chart with evidence you can check, and tests strategies against NEPHROPLUS's own history. Try: “Why has NEPHROPLUS moved over the last three months?” · “Backtest a 50-day moving-average crossover on NEPHROPLUS over five years” · “Compare NEPHROPLUS with ENTERO on margins and valuation”
Frequently asked questions about Nephrocare Health Services
What is the share price of Nephrocare Health Services today?
Nephrocare Health Services (NSE: NEPHROPLUS) last closed at ₹599.90 on 22 Oct 2026. Its 52-week high is ₹781.50 and its 52-week low is ₹446.00.
What is the market cap of Nephrocare Health Services?
Nephrocare Health Services' market capitalisation is ₹6,019 Cr (₹6,019 Cr) at the 22 Oct 2026 close, ranking 728th among the NSE companies Pivot tracks.
What is the P/E ratio of Nephrocare Health Services?
Nephrocare Health Services trades at a trailing P/E of 74.1. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 40.
What is the ROE and ROCE of Nephrocare Health Services?
Return on equity was 6.9% in FY26 and return on capital employed was 13.7% in FY26 (consolidated figures).
Is Nephrocare Health Services a debt-free company?
No. Nephrocare Health Services' debt-to-equity ratio was 0.07 in FY26, with total debt of ₹45 Cr.
What were Nephrocare Health Services' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Nephrocare Health Services reported revenue of ₹266 Cr, +21.2% year on year, and net profit of ₹33 Cr, +34.5% year on year.
What is the shareholding pattern of Nephrocare Health Services?
As of 30 Jun 2026: promoters 63.85%, foreign institutions 8.78%, domestic institutions 9.05%, non-institutions 18.32%.
Who are Nephrocare Health Services' competitors?
The listed Pharma & Healthcare companies closest to Nephrocare Health Services by market cap are Entero Healthcare Solutions, Kovai Medical Center & Hospital, Sun Pharma Advanced Research Company, Senores Pharmaceuticals, Innova Captab and FDC.
Is Nephrocare Health Services a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Nephrocare Health Services' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NEPHROPLUS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text